6.61

0.46% 0.03

After Hours: 6.59 -0.02 -0.30%

Mannkind Corp (MNKD)

Overview News Price History Option Chain Financials Why MNKD Down? Discussions Forecast Stock Split

Mannkind Corp stock is traded at $6.61, with a volume of 3.20M. It is up +0.46% in the last 24 hours and up +1.07% over the past month. MannKind Corp is a biopharmaceutical company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. Its approved product, Afrezza (insulin human) Inhalation Powder, is an ultra-rapid-acting inhaled insulin used to improve glycemic control in adults with diabetes. The product consists of a dry powder formulation of human insulin delivered from a small portable inhaler.

Previous Close:

$6.58

Open:

$6.58

24h Volume:

3.20M

Relative Volume:

1.23

Market Cap:

$1.82B

Revenue:

$248.37M

Net Income/Loss:

$11.74M

P/E Ratio:

-34.79

EPS:

-0.19

Net Cash Flow:

$18.24M

1W Performance:

-3.92%

1M Performance:

+1.07%

6M Performance:

+38.28%

1Y Performance:

+87.78%

1-Day Range:

$6.40

$6.675

1-Week Range:

$6.26

$7.005

52-Week Range:

$3.17

$7.63

Mannkind Corp Stock (MNKD) Company Profile

Name

Mannkind Corp

Sector

Healthcare (1200)

Industry

Biotechnology (682)

Phone

818-661-5000

Address

1 CASPER STREET, DANBURY, CA

Employee

414

Twitter

@MannKindCorp

Next Earnings Date

2024-11-07

Latest SEC Filings

MNKD's Discussions on Twitter

Compare MNKD with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
MNKD Mannkind Corp	6.61	1.82B	248.37M	11.74M	18.24M	-0.19
VRTX Vertex Pharmaceuticals Inc	464.56	119.70B	10.63B	-479.80M	-1.35B	13.33
REGN Regeneron Pharmaceuticals Inc	754.87	82.75B	13.85B	4.65B	3.32B	35.06
ARGX Argen X Se Adr	614.59	36.73B	1.86B	-40.29M	-1.28B	-4.16
ALNY Alnylam Pharmaceuticals Inc	253.74	32.53B	2.09B	-332.26M	16.06M	-4.14
BNTX Biontech Se Adr	120.72	28.50B	3.30B	-501.07M	1.03B	11.54

Mannkind Corp Stock (MNKD) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Sep-09-24	Resumed	Leerink Partners	Outperform
Jun-13-24	Initiated	Rodman & Renshaw	Buy
Oct-10-23	Initiated	Wedbush	Outperform
May-14-21	Initiated	RBC Capital Mkts	Sector Perform
Dec-24-19	Initiated	Oppenheimer	Outperform
Oct-25-19	Initiated	Cantor Fitzgerald	Overweight
May-14-19	Initiated	BTIG Research	Buy
Mar-04-19	Initiated	SVB Leerink	Outperform
Feb-22-19	Initiated	SVB Leerink	Outperform
Feb-28-18	Downgrade	Maxim Group	Hold → Sell
Nov-01-17	Downgrade	Maxim Group	Buy → Hold
Oct-10-17	Initiated	H.C. Wainwright	Buy
Oct-06-17	Reiterated	Maxim Group	Buy
Aug-11-17	Initiated	Maxim Group	Buy
May-10-16	Reiterated	Piper Jaffray	Underweight
May-10-16	Reiterated	RBC Capital Mkts	Underperform
Jan-06-16	Reiterated	Piper Jaffray	Underweight
Jan-06-16	Reiterated	RBC Capital Mkts	Underperform
Nov-04-15	Downgrade	RBC Capital Mkts	Outperform → Underperform
Sep-09-15	Downgrade	Piper Jaffray	Neutral → Underweight
Aug-03-15	Reiterated	RBC Capital Mkts	Outperform
May-11-15	Downgrade	JP Morgan	Neutral → Underweight
May-11-15	Reiterated	MLV & Co	Hold
Apr-16-15	Reiterated	RBC Capital Mkts	Outperform

View All

Mannkind Corp Stock (MNKD) Latest News

Nov 25, 2024

Insider Sell Alert: Steven Binder Sells 67,536 Shares of MannKin - GuruFocus.com

Nov 25, 2024

MannKind director Steven Binder sells $465k in stock - Investing.com India

Nov 25, 2024

MannKind director Steven Binder sells $465k in stock By Investing.com - Investing.com South Africa

Nov 25, 2024

MannKind (NASDAQ:MNKD) Downgraded to Hold Rating by StockNews.com - Defense World

Nov 25, 2024

Nov 24, 2024

Principal Financial Group Inc. Purchases 134,937 Shares of MannKind Co. (NASDAQ:MNKD) - Defense World

Nov 24, 2024

Nov 22, 2024

MannKind Co. (NASDAQ:MNKD) Shares Bought by Connor Clark & Lunn Investment Management Ltd. - MarketBeat

Nov 22, 2024

Nov 21, 2024

MannKind (STU:NNFN) Inventories, Raw Materials & Components : €5.8 Mil (As of Sep. 2024) - GuruFocus.com

Nov 21, 2024

Nov 20, 2024

MannKind Shares Soar to Over 8-Year Highs on United Therapeutics’ Tyvaso Revenue Surge: Retail Is Optimistic - MSN

Nov 20, 2024

Nov 19, 2024

MannKind Corp director Steven Binder sells $456,563 in stock By Investing.com - Investing.com Nigeria

Nov 19, 2024

MannKind Corp director Steven Binder sells $456,563 in stock - Investing.com

Nov 19, 2024

Nov 11, 2024

Insulin Pump Market Report 2024-2035, Featuring Profiles of Leading Players Including Beta Bionics, CeQur, EOFlow, Insulet, LA Roche, MannKind, Medtronic, Medtrum Technologies and MicroPort - Yahoo Finance

Nov 11, 2024

Nov 09, 2024

MannKind Corporation (NASDAQ:MNKD) Q3 2024 Earnings Call Transcript - Insider Monkey

Nov 09, 2024

MannKind Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance

Nov 09, 2024

Insider Sale: Chief People & Workpl Officer Stuart Tross Sells 5 - GuruFocus.com

Nov 09, 2024

Nov 08, 2024

MannKind Corp's chief people officer Stuart Tross sells $403,700 in stock - Investing.com Australia

Nov 08, 2024

Earnings call: MannKind sees growth and pipeline progress in Q3 2024 - Investing.com

Nov 08, 2024

MannKind Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com

Nov 08, 2024

Pulmatrix Announces Third Quarter 2024 Financial Results and Provides Corporate Update - Quantisnow

Nov 08, 2024